Citations (135)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (21)
Aditya Rathi, Vipul Kumar & Durai Sundar. (2023) Insights into the potential of withanolides as Phosphodiesterase-4 (PDE4D) inhibitors. Journal of Biomolecular Structure and Dynamics 41:6, pages 2108-2117.
Read now
Read now
Vishalakshi Viswanath, Pradnya Joshi, Prakash Lawate, Dakshata Tare, Dhiraj Dhoot, Namrata Mahadkar & Hanmant Barkate. (2022) An Open-Label, Randomized, Prospective, Comparative, Three-Arm Clinical Trial to Evaluate the Safety and Effectiveness of Apremilast with Three Different Titration Methods in Patients with Chronic Plaque Psoriasis in India. Psoriasis: Targets and Therapy 12, pages 53-61.
Read now
Read now
Gaëlle Clavel, Marie-Christophe Boissier, Johanna Sigaux & Luca Semerano. (2017) Developments with experimental and investigational drugs for axial spondyloarthritis. Expert Opinion on Investigational Drugs 26:7, pages 833-842.
Read now
Read now
Jerry J Flores, Yang Zhang, Damon W Klebe, Tim Lekic, Weiling Fu & John H Zhang. (2014) Small molecule inhibitors in the treatment of cerebral ischemia. Expert Opinion on Pharmacotherapy 15:5, pages 659-680.
Read now
Read now
Maliheh Safavi, Maryam Baeeri & Mohammad Abdollahi. (2013) New methods for the discovery and synthesis of PDE7 inhibitors as new drugs for neurological and inflammatory disorders. Expert Opinion on Drug Discovery 8:6, pages 733-751.
Read now
Read now
Marianna Szczypka & Bożena Obmińska-Mrukowicz. (2010) The effects of selective and nonselective phosphodiesterase inhibitors on phagocytic cells in mice. Immunopharmacology and Immunotoxicology 32:3, pages 507-513.
Read now
Read now
Simone Di Giovanni. (2009) Molecular targets for axon regeneration: focus on the intrinsic pathways. Expert Opinion on Therapeutic Targets 13:12, pages 1387-1398.
Read now
Read now
Jitendra
M. Gajera, Laxmikant
A. Gharat & Aniket
V. Farande. (2007) Cyclopentyl: A Novel Protective Group for Phenols. Synthetic Communications 37:24, pages 4309-4312.
Read now
Read now
Hazel J Dyke. (2007) Novel 5,6-dihydropyrazolo-[3,4-E][1,4]diazepin-4 (1H)-one derivatives for the treatment of asthma and chronic obstructive pulmonary disease. Expert Opinion on Therapeutic Patents 17:9, pages 1183-1189.
Read now
Read now
Jitendra
M. Gajera, Laxmikant
A. Gharat & Aniket
V. Farande. (2007) Cyclopentyl: A Novel Protective Group for Phenols. Synthetic Communications 37:17, pages 2877-2880.
Read now
Read now
William M Brown. (2007) Treating COPD with PDE 4 inhibitors. International Journal of Chronic Obstructive Pulmonary Disease 2:4, pages 517-533.
Read now
Read now
Keith Q. Tanis & Ronald S. Duman. (2007) Intracellular signaling pathways pave roads to recovery for mood disorders. Annals of Medicine 39:7, pages 531-544.
Read now
Read now
R Al-Jamal, WAH Wallace & DJ Harrison. (2005) Gene therapy for chronic obstructive pulmonary disease: twilight or triumph?. Expert Opinion on Biological Therapy 5:3, pages 333-346.
Read now
Read now
. (2005) Novel 4-aminopyrazolo[3,4-b]pyridine PDE4 inhibitors. Expert Opinion on Therapeutic Patents 15:1, pages 111-114.
Read now
Read now
Robert Vink, J. J. Donkin, M. I. Cruz, Alan J Nimmo & Ibolja Cernak. (2004) A Substance P Antagonist Increases Brain Intracellular Free Magnesium Concentration after Diffuse Traumatic Brain Injury in Rats. Journal of the American College of Nutrition 23:5, pages 538S-540S.
Read now
Read now
Hae-Hyuk Lee & Margitta Worm. (2004) New compounds for the treatment of eczematous skin diseases. Expert Opinion on Therapeutic Patents 14:9, pages 1257-1271.
Read now
Read now
A. S. Kalgutkar, E. Choo, T. J. Taylor & A. Marfat. (2004) Disposition of CP-671, 305, a selective phosphodiesterase 4 inhibitor in preclinical species. Xenobiotica 34:8, pages 755-770.
Read now
Read now
Hans Michael Haitchi & Stephen T Holgate. (2004) New strategies in the treatment and prevention of allergic diseases. Expert Opinion on Investigational Drugs 13:2, pages 107-124.
Read now
Read now
. (2003) A novel phosphodiesterase 4 inhibitor template. Expert Opinion on Therapeutic Patents 13:6, pages 929-933.
Read now
Read now
Heinz Wiendl & Bernd C Kieseier. (2003) Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies. Expert Opinion on Investigational Drugs 12:4, pages 689-712.
Read now
Read now
Peter Norman. (2002) PDE4 inhibitors 2001. Patent and literature activity 2000 - September 2001. Expert Opinion on Therapeutic Patents 12:1, pages 93-112.
Read now
Read now
Articles from other publishers (114)
Maheedhar Kodali, Tanvi Jankay, Ashok K. Shetty & Doodipala Samba Reddy. (2023) Pathophysiological basis and promise of experimental therapies for Gulf War Illness, a chronic neuropsychiatric syndrome in veterans. Psychopharmacology 240:4, pages 673-697.
Crossref
Crossref
Yulia A. Antonova, Yulia V. Nelyubina, Sema L. Ioffe & Andrey A. Tabolin. (2023) [3+3]-Annulation of Cyclic Nitronates with Vinyl Diazoacetates: Diastereoselective Synthesis of Partially Saturated [1,2]Oxazino[2,3-b][1,2]oxazines and Their Base-Promoted Ring Contraction to Pyrrolo[1,2-b][1,2]oxazine Derivatives. Molecules 28:7, pages 3025.
Crossref
Crossref
Andrey D. Bondarev, Misty M. Attwood, Jörgen Jonsson, Vladimir N. Chubarev, Vadim V. Tarasov, Wen Liu & Helgi B. Schiöth. (2022) Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules. Frontiers in Pharmacology 13.
Crossref
Crossref
Ran Gao, Wenjun Guo, Tianfei Fan, Junling Pang, Yangfeng Hou, Xiaohang Feng, Bolun Li, Weipeng Ge, Tianhui Fan, Tiantian Zhang, Jiakai Lu, He Jing, Mu Jin, Chen Yan & Jing Wang. (2022) Phosphodiesterase 4D contributes to angiotensin II-induced abdominal aortic aneurysm through smooth muscle cell apoptosis. Experimental & Molecular Medicine 54:8, pages 1201-1213.
Crossref
Crossref
Komal Thapa, Thakur Gurjeet Singh & Amarjot Kaur. (2021) Cyclic nucleotide phosphodiesterase inhibition as a potential therapeutic target in renal ischemia reperfusion injury. Life Sciences 282, pages 119843.
Crossref
Crossref
Donald J. AbrahamJohn G. Montana, Hazel J. Dyke, J. Craig Fox & Nicholas C. Ray. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
47
.
Nam-Shik Kim, Zhexing Wen, Jing Liu, Ying Zhou, Ziyuan Guo, Chongchong Xu, Yu-Ting Lin, Ki-Jun Yoon, Junhyun Park, Michelle Cho, Minji Kim, Xinyuan Wang, Huimei Yu, Srilatha Sakamuru, Kimberly M. Christian, Kuei-sen Hsu, Menghang Xia, Weidong Li, Christopher A. Ross, Russell L. Margolis, Xin-Yun Lu, Hongjun Song & Guo-li Ming. (2021) Pharmacological rescue in patient iPSC and mouse models with a rare DISC1 mutation. Nature Communications 12:1.
Crossref
Crossref
Andrea Weiss, Sandra Porter, Dmitry Rozenberg, Erin O'Connor, Tiffany Lee, Meyer Balter & Kirsten Wentlandt. (2020) Chronic Obstructive Pulmonary Disease: A Palliative Medicine Review of the Disease, Its Therapies, and Drug Interactions. Journal of Pain and Symptom Management 60:1, pages 135-150.
Crossref
Crossref
Jiahong Zhong, Wenli Dong, Yunyun Qin, Jinfeng Xie, Jiao Xiao, Jiangping Xu & Haitao Wang. (2020) Roflupram exerts neuroprotection via activation of CREB/PGC‐1α signalling in experimental models of Parkinson's disease. British Journal of Pharmacology 177:10, pages 2333-2350.
Crossref
Crossref
Jose A. Morales-Garcia, Sandra Alonso-Gil, Ángel Santos & Ana Perez-Castillo. (2019) Phosphodiesterase 7 Regulation in Cellular and Rodent Models of Parkinson’s Disease. Molecular Neurobiology 57:2, pages 806-822.
Crossref
Crossref
Rebecca Rothe, Sabine Schulze, Christin Neuber, Sandra Hauser, Stefan Rammelt & Jens Pietzsch. (2020) Adjuvant drug-assisted bone healing: Part II – Modulation of angiogenesis. Clinical Hemorheology and Microcirculation 73:3, pages 409-438.
Crossref
Crossref
Eirini Vagena, Jae Kyu Ryu, Bernat Baeza-Raja, Nicola M. Walsh, Catriona Syme, Jonathan P. Day, Miles D. Houslay & George S. Baillie. (2019) A high-fat diet promotes depression-like behavior in mice by suppressing hypothalamic PKA signaling. Translational Psychiatry 9:1.
Crossref
Crossref
Bahia A. Moussa, Asmaa A. El‐Zaher, Mohamed K. El‐Ashrey & Marwa A. Fouad. (2019) Roflumilast analogs with improved metabolic stability, plasma protein binding, and pharmacokinetic profile. Drug Testing and Analysis 11:6, pages 886-897.
Crossref
Crossref
Banrida Wahlang, Craig McClain, Shirish Barve & Leila Gobejishvili. (2018) Role of cAMP and phosphodiesterase signaling in liver health and disease. Cellular Signalling 49, pages 105-115.
Crossref
Crossref
Murat Torgutalp & Denis Poddubnyy. (2018) Emerging treatment options for spondyloarthritis. Best Practice & Research Clinical Rheumatology 32:3, pages 472-484.
Crossref
Crossref
Yucong Peng, Jianxiang Jin, Linfeng Fan, Hangzhe Xu, Pingyou He, Jianru Li, Ting Chen, Wu Ruan & Gao Chen. (2018) Rolipram Attenuates Early Brain Injury Following Experimental Subarachnoid Hemorrhage in Rats: Possibly via Regulating the SIRT1/NF-κB Pathway. Neurochemical Research 43:4, pages 785-795.
Crossref
Crossref
Qun Li, Yucong Peng, Linfeng Fan, Hangzhe Xu, Pingyou He, Shenglong Cao, Jianru Li, Ting Chen, Wu Ruan & Gao Chen. (2018) Phosphodiesterase-4 inhibition confers a neuroprotective efficacy against early brain injury following experimental subarachnoid hemorrhage in rats by attenuating neuronal apoptosis through the SIRT1/Akt pathway. Biomedicine & Pharmacotherapy 99, pages 947-955.
Crossref
Crossref
Chuang Wang, Zhen Wang, Mengmeng Li, Chenli Li, Hanjie Yu, Dongsheng Zhou & Zhongming Chen. 2017. Mechanisms of Neuroinflammation. Mechanisms of Neuroinflammation.
Mari SakaiTokiko SuzukiKengo TomitaShigeyuki YamashitaSailesh PalikheKohshi Hattori, Naoki YoshimuraNaoyuki Matsuda & Yuichi Hattori. (2017) Diminished responsiveness to dobutamine as an inotrope in mice with cecal ligation and puncture-induced sepsis: attribution to phosphodiesterase 4 upregulation. American Journal of Physiology-Heart and Circulatory Physiology 312:6, pages H1224-H1237.
Crossref
Crossref
Lígia Mendes Soares, Jochen De Vry, Harry W.M. Steinbusch, Humberto Milani, Jos Prickaerts & Rúbia M. Weffort de Oliveira. (2016) Rolipram improves cognition, reduces anxiety- and despair-like behaviors and impacts hippocampal neuroplasticity after transient global cerebral ischemia. Neuroscience 326, pages 69-83.
Crossref
Crossref
Susann Schröder, Barbara Wenzel, Winnie Deuther-Conrad, Matthias Scheunemann & Peter Brust. (2016) Novel Radioligands for Cyclic Nucleotide Phosphodiesterase Imaging with Positron Emission Tomography: An Update on Developments Since 2012. Molecules 21:5, pages 650.
Crossref
Crossref
Jacques Le Roux, Caroline Leriche, Philippe Chamiot-Clerc, John Feutrill, Frank Halley, David Papin, Nathalie Derimay, Christelle Mugler, Claudine Grépin & Laurent Schio. (2016) Preparation and optimization of pyrazolo[1,5- a ]pyrimidines as new potent PDE4 inhibitors. Bioorganic & Medicinal Chemistry Letters 26:2, pages 454-459.
Crossref
Crossref
Miguel Perez-Aso, M. Carmen Montesinos, Aránzazu Mediero, Tuere Wilder, Peter H. Schafer & Bruce Cronstein. (2015) Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors. Arthritis Research & Therapy 17:1.
Crossref
Crossref
Steven P Vickers, David Hackett, Fraser Murray, Peter H Hutson & David J Heal. (2015) Effects of lisdexamfetamine in a rat model of binge-eating. Journal of Psychopharmacology 29:12, pages 1290-1307.
Crossref
Crossref
Amitava Mitra, Aquiles Leyes, Kimberly Manser, Brad Roadcap, Christine Mestre, Daniel Tatosian, Lan Jin & Naoto Uemura. (2015) Use of Minipig Skin Biopsy Model as an Innovative Tool to Design Topical Formulation to Achieve Desired Pharmacokinetics in Humans. Journal of Pharmaceutical Sciences 104:5, pages 1701-1708.
Crossref
Crossref
Chuang Wang, Jianrui Zhang, Yang Lu, Peipei Lin, Tonghe Pan, Xin Zhao, Aiming Liu, Qinwen Wang, Wenhua Zhou & Han-Ting Zhang. (2014) Antidepressant-like effects of the phosphodiesterase-4 inhibitor etazolate and phosphodiesterase-5 inhibitor sildenafil via cyclic AMP or cyclic GMP signaling in mice. Metabolic Brain Disease 29:3, pages 673-682.
Crossref
Crossref
Rolf T. HansenIIIIII, Marco Conti & Han-Ting Zhang. (2014) Mice deficient in phosphodiesterase-4A display anxiogenic-like behavior. Psychopharmacology 231:15, pages 2941-2954.
Crossref
Crossref
J. Guo, P. Lin, X. Zhao, J. Zhang, X. Wei, Q. Wang & C. Wang. (2014) Etazolate abrogates the lipopolysaccharide (LPS)-induced downregulation of the cAMP/pCREB/BDNF signaling, neuroinflammatory response and depressive-like behavior in mice. Neuroscience 263, pages 1-14.
Crossref
Crossref
Delphine LissaLaura SenovillaSantiago Rello-VaronaIlio VitaleMickaël MichaudFederico PietrocolaAlice BoilèveFlorine ObristChloé BordenavePauline GarciaJudith MichelsMohamed JemaàOliver KeppMaria CastedoGuido Kroemer. (2014) Resveratrol and aspirin eliminate tetraploid cells for anticancer chemoprevention. Proceedings of the National Academy of Sciences 111:8, pages 3020-3025.
Crossref
Crossref
Scott Sloka, Luanne M Metz, Walter Hader, Yves Starreveld & V Wee Yong. (2013) Reduction of microglial activity in a model of multiple sclerosis by dipyridamole. Journal of Neuroinflammation 10:1.
Crossref
Crossref
Neal Kumar, Ari M Goldminz, Noori Kim & Alice B Gottlieb. (2013) Phosphodiesterase 4-targeted treatments for autoimmune diseases. BMC Medicine 11:1.
Crossref
Crossref
Peter Kraft, Tobias Schwarz, Eva Göb, Nadine Heydenreich, Marc Brede, Sven G. Meuth & Christoph Kleinschnitz. (2013) The phosphodiesterase-4 inhibitor rolipram protects from ischemic stroke in mice by reducing blood–brain-barrier damage, inflammation and thrombosis. Experimental Neurology 247, pages 80-90.
Crossref
Crossref
Daniel I. Pérez, Marco Pistolozzi, Valle Palomo, Miriam Redondo, Cecilia Fortugno, Carmen Gil, Guy Felix, Ana Martinez & Carlo Bertucci. (2012) 5-Imino-1,2-4-thiadiazoles and quinazolines derivatives as glycogen synthase kinase 3β (GSK-3β) and phosphodiesterase 7 (PDE7) inhibitors: Determination of blood–brain barrier penetration and binding to human serum albumin. European Journal of Pharmaceutical Sciences 45:5, pages 677-684.
Crossref
Crossref
Rongze Kuang, Ho-Jane Shue, Li Xiao, David J. Blythin, Neng-Yang Shih, Xiao Chen, Danlin Gu, John Schwerdt, Ling Lin, Pauline C. Ting, Jianhua Cao, Robert Aslanian, John J. Piwinski, Daniel Prelusky, Ping Wu, Ji Zhang, Xiang Zhang, Chander S. Celly, Motasim Billah & Peng Wang. (2012) Discovery of oxazole-based PDE4 inhibitors with picomolar potency. Bioorganic & Medicinal Chemistry Letters 22:7, pages 2594-2597.
Crossref
Crossref
M. Oudega, E.J. Bradbury & M.S. Ramer. 2012. Spinal Cord Injury. Spinal Cord Injury
617
636
.
B. Mark Woerner & Joshua B. Rubin. 2012. Tumors of the Central Nervous System, Volume 4. Tumors of the Central Nervous System, Volume 4
119
127
.
Nicholas D. Bland, Cuihua Wang, Craig Tallman, Alden E. Gustafson, Zhouxi Wang, Trent D. Ashton, Stefan O. Ochiana, Gregory McAllister, Kristina Cotter, Anna P. Fang, Lara Gechijian, Norman Garceau, Rajiv Gangurde, Ron Ortenberg, Mary Jo Ondrechen, Robert K. Campbell & Michael P. Pollastri. (2011) Pharmacological Validation of Trypanosoma brucei Phosphodiesterases B1 and B2 as Druggable Targets for African Sleeping Sickness. Journal of Medicinal Chemistry 54:23, pages 8188-8194.
Crossref
Crossref
Kris Rutten, Tanya L. Wallace, Melissa Works, Jos Prickaerts, Arjan Blokland, Thomas J. Novak, Luca Santarelli & Dinah L. Misner. (2011) Enhanced long-term depression and impaired reversal learning in phosphodiesterase 4B-knockout (PDE4B−/−) mice. Neuropharmacology 61:1-2, pages 138-147.
Crossref
Crossref
Christopher A. Iannotti, Megan Clark, Kevin P. Horn, Nico van Rooijen, Jerry Silver & Michael P. Steinmetz. (2011) A combination immunomodulatory treatment promotes neuroprotection and locomotor recovery after contusion SCI. Experimental Neurology 230:1, pages 3-15.
Crossref
Crossref
Howard Kim, Tasneem Zahir, Charles H. Tator & Molly S. Shoichet. (2011) Effects of Dibutyryl Cyclic-AMP on Survival and Neuronal Differentiation of Neural Stem/Progenitor Cells Transplanted into Spinal Cord Injured Rats. PLoS ONE 6:6, pages e21744.
Crossref
Crossref
Cathy J. Tralau-Stewart, Richard A. Williamson, Anthony T. Nials, Michele Gascoigne, John Dawson, Graham J. Hart, Anthony D. R. Angell, Yemisi E. Solanke, Fiona S. Lucas, Joanne Wiseman, Peter Ward, Lisa E. Ranshaw & Richard G. Knowles. (2011) GSK256066, an Exceptionally High-Affinity and Selective Inhibitor of Phosphodiesterase 4 Suitable for Administration by Inhalation: In Vitro, Kinetic, and In Vivo Characterization. Journal of Pharmacology and Experimental Therapeutics 337:1, pages 145-154.
Crossref
Crossref
Barbara Rossi, Elena Zenaro, Stefano Angiari, Linda Ottoboni, Simona Bach, Laura Piccio, Enrica C. Pietronigro, Elio Scarpini, Mariella Fusco, Alberta Leon & Gabriela Constantin. (2011) Inverse agonism of cannabinoid CB1 receptor blocks the adhesion of encephalitogenic T cells in inflamed brain venules by a protein kinase A-dependent mechanism. Journal of Neuroimmunology 233:1-2, pages 97-105.
Crossref
Crossref
Irene Paterniti, Emanuela Mazzon, Carmen Gil, Daniela Impellizzeri, Valle Palomo, Myriam Redondo, Daniel I. Perez, Emanuela Esposito, Ana Martinez & Salvatore Cuzzocrea. (2011) PDE 7 Inhibitors: New Potential Drugs for the Therapy of Spinal Cord Injury. PLoS ONE 6:1, pages e15937.
Crossref
Crossref
Yun-Feng Li, Yu-Fang Cheng, Ying Huang, Marco Conti, Steven P. Wilson, James M. O'Donnell & Han-Ting Zhang. (2011) Phosphodiesterase-4D Knock-Out and RNA Interference-Mediated Knock-Down Enhance Memory and Increase Hippocampal Neurogenesis via Increased cAMP Signaling. The Journal of Neuroscience 31:1, pages 172-183.
Crossref
Crossref
Jin Sook Song, Hyeong Jin Rho, Jong Shik Park, Min Sun Kim, Byung Hoi Lee, Jeong-won Seo, Dong Ju Jeon, Hyae Gyeong Cheon, Sung Hoon Ahn, Kwang-il Kwon & Myung Ae Bae. (2011) Preclinical Pharmacokinetics of PDE-310, a Novel PDE4 Inhibitor. Drug Metabolism and Pharmacokinetics 26:2, pages 192-200.
Crossref
Crossref
B. Mark Woerner & Joshua B. Rubin. 2011. Methods of Cancer Diagnosis, Therapy, and Prognosis. Methods of Cancer Diagnosis, Therapy, and Prognosis
71
82
.
Mark A. Giembycz & Robert Newton. 2011. Phosphodiesterases as Drug Targets. Phosphodiesterases as Drug Targets
415
446
.
Anna Klukovits, Judit Verli, George Falkay & Róbert Gáspár. (2010) Improving the relaxing effect of terbutaline with phosphodiesterase inhibitors: Studies on pregnant rat uteri in vitro. Life Sciences 87:23-26, pages 733-737.
Crossref
Crossref
Marianna Szczypka & Bożena Obmińska-Mrukowicz. (2010) Modulating effects of nonselective and selective phosphodiesterase inhibitors on lymphocyte subsets and humoral immune response in mice. Pharmacological Reports 62:6, pages 1148-1158.
Crossref
Crossref
Lyle C. Fonseca, Shruta S. Dadarkar, Aurelio S. Lobo, Ashish C. Suthar, Vijay S. Chauhan, Shanthi Chandrababu, Somesh D. Sharma, Nilesh M. Dagia & Muralidhara Padigaru. (2010) 7-hydroxyfrullanolide, a sesquiterpene lactone, inhibits pro-inflammatory cytokine production from immune cells and is orally efficacious in animal models of inflammation. European Journal of Pharmacology 644:1-3, pages 220-229.
Crossref
Crossref
Arata Yanagisawa, Koichiro Nishimura, Kyoji Ando, Tetsuya Nezu, Ayako Maki, Sachiko Kato, Wakako Tamaki, Eiichiro Imai & Shin-ichiro Mohri. (2010) A Practical Synthesis of the PDE4 Inhibitor, KW-4490. Organic Process Research & Development 14:5, pages 1182-1187.
Crossref
Crossref
Joachim Hoppmann, Christin Galetzka, Norbert Höfgen, Chris Rundfeldt, Wolfgang Bämer & Manfred Kietzmann. (2005) The phosphodiesterase 4 inhibitor AWD 12–281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice. Journal of Pharmacy and Pharmacology 57:12, pages 1609-1617.
Crossref
Crossref
Wolfgang Bäumer, Gilbert Gorr, Joachim Hoppmann, Andreas M Ehinger, Chris Rundfeldt & Manfred Kietzmann. (2003) AWD 12–281, a highly selective phosphodiesterase 4 inhibitor, is effective in the prevention and treatment of inflammatory reactions in a model of allergic dermatitis. Journal of Pharmacy and Pharmacology 55:8, pages 1107-1114.
Crossref
Crossref
Roja Rahimi, Sima Ghiasi, Hanieh Azimi, Sima Fakhari & Mohammad Abdollahi. (2010) A review of the herbal phosphodiesterase inhibitors; Future perspective of new drugs. Cytokine 49:2, pages 123-129.
Crossref
Crossref
Donald J. AbrahamJohn G. Montana, Hazel J. Dyke, J. Craig Fox & Nicholas C. Ray. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
747
790
.
Joseph M. Antony & Christopher Power. 2016. Inflammatory Diseases of the Central Nervous System. Inflammatory Diseases of the Central Nervous System
245
260
.
. 2016. Inflammatory Diseases of the Central Nervous System. Inflammatory Diseases of the Central Nervous System
201
260
.
Tania Castaño, Huanchen Wang, Nuria E. Campillo, Sara Ballester, Coral González-García, Javier Hernández, Concepción Pérez, Jimena Cuenca, Ana Pérez-Castillo, Ana Martínez, Oscar Huertas, José Luis Gelpí, F. Javier Luque, Hengming Ke & Carmen Gil. (2009) Synthesis, Structural Analysis, and Biological Evaluation of Thioxoquinazoline Derivatives as Phosphodiesterase 7 Inhibitors. ChemMedChem 4:5, pages 866-876.
Crossref
Crossref
Sondra T. Bland, Mark R. Hutchinson, Steven F. Maier, Linda R. Watkins & Kirk W. Johnson. (2009) The glial activation inhibitor AV411 reduces morphine-induced nucleus accumbens dopamine release. Brain, Behavior, and Immunity 23:4, pages 492-497.
Crossref
Crossref
Simon F. Crowe, Joanna Neath & Matthew W. Hale. (2009) The type 4 phosphodiesterase inhibitors rolipram and YM976 facilitate recall of the weak version of the passive avoidance task in the day-old chick. Pharmacology Biochemistry and Behavior 92:2, pages 224-230.
Crossref
Crossref
Mark A. Giembycz. 2010. Allergy Frontiers: Therapy and Prevention. Allergy Frontiers: Therapy and Prevention
105
132
.
Sanjay J Mathew, Husseini K Manji & Dennis S Charney. (2008) Novel Drugs and Therapeutic Targets for Severe Mood Disorders. Neuropsychopharmacology 33:9, pages 2080-2092.
Crossref
Crossref
Ana Castro, María José Jerez, Carmen Gil, Félix Calderón, Teresa Doménech, Arsenio Nueda & Ana Martínez. (2008) CODES, a novel procedure for ligand-based virtual screening: PDE7 inhibitors as an application example. European Journal of Medicinal Chemistry 43:7, pages 1349-1359.
Crossref
Crossref
Michael J. Marino, Lars J. S. Knutsen & Michael Williams. (2008) Emerging Opportunities for Antipsychotic Drug Discovery in the Postgenomic Era. Journal of Medicinal Chemistry 51:5, pages 1077-1107.
Crossref
Crossref
Mark W. Irvine, Graham L. Patrick, Justin Kewney, Stuart F. Hastings & Simon J. MacKenzie. (2008) Rhodanine derivatives as novel inhibitors of PDE4. Bioorganic & Medicinal Chemistry Letters 18:6, pages 2032-2037.
Crossref
Crossref
Laura KahmannPeter UciechowskiSabine WarmuthBirgit PlümäkersAxel M. GressnerMarco MalavoltaEugenio MocchegianiLothar Rink. (2008) Zinc Supplementation in the Elderly Reduces Spontaneous Inflammatory Cytokine Release and Restores T Cell Functions. Rejuvenation Research 11:1, pages 227-237.
Crossref
Crossref
Shuchi Nagar, Md Ataul Islam, Suvadra Das, Arup Mukherjee & Achintya Saha. (2008) Pharmacophore mapping of flavone derivatives for aromatase inhibition. Molecular Diversity 12:1, pages 65-76.
Crossref
Crossref
F. Douglas Ivey, Lili Wang, Didem Demirbas, Christina Allain & Charles S. Hoffman. (2008) Development of a Fission Yeast-Based High-Throughput Screen to Identify Chemical Regulators of cAMP Phosphodiesterases. SLAS Discovery 13:1, pages 62-71.
Crossref
Crossref
A. van Nieuw AmerongenA. van Nieuw Amerongen. 2008. Speeksel, speekselklieren en mondgezondheid. Speeksel, speekselklieren en mondgezondheid
93
110
.
A. van Nieuw AmerongenA. van Nieuw Amerongen. 2008. Speeksel, speekselklieren en mondgezondheid. Speeksel, speekselklieren en mondgezondheid
421
430
.
Elisabet Reyes-Irisarri, Antonio J. Sánchez, Juan Antonio García-Merino & Guadalupe Mengod. (2007) Selective Induction of cAMP Phosphodiesterase PDE4B2 Expression in Experimental Autoimmune Encephalomyelitis. Journal of Neuropathology and Experimental Neurology 66:10, pages 923-931.
Crossref
Crossref
Verena von Bülow, Svenja Dubben, Gabriela Engelhardt, Silke Hebel, Birgit Plümäkers, Holger Heine, Lothar Rink & Hajo Haase. (2007) Zinc-Dependent Suppression of TNF-α Production Is Mediated by Protein Kinase A-Induced Inhibition of Raf-1, IκB Kinase β, and NF-κB. The Journal of Immunology 179:6, pages 4180-4186.
Crossref
Crossref
Rongze Kuang, Ho-Jane Shue, David J. Blythin, Neng-Yang Shih, Danlin Gu, Xiao Chen, John Schwerdt, Ling Lin, Pauline C. Ting, Xiaohong Zhu, Robert Aslanian, John J. Piwinski, Li Xiao, Daniel Prelusky, Ping Wu, Ji Zhang, Xiang Zhang, Chander S. Celly, Michael Minnicozzi, Motasim Billah & Peng Wang. (2007) Discovery of a highly potent series of oxazole-based phosphodiesterase 4 inhibitors. Bioorganic & Medicinal Chemistry Letters 17:18, pages 5150-5154.
Crossref
Crossref
C. Kleinschnitz, S.G. Meuth, B.C. Kieseier & H. Wiendl. (2007) Multiple-Sklerose-Update zur Pathophysiologie und neuen immuntherapeutischen AnsätzenUpdate on pathophysiologic and immunotherapeutic approaches for the treatment of multiple sclerosis. Der Nervenarzt 78:8, pages 883-911.
Crossref
Crossref
Lang-Chu Lau & P. Ganesan Adaikan. (2007) Effect of Sildenafil and Rolipram on Adrenergic Responses in Isolated Human and Monkey Corpus Cavernosum. European Urology 52:1, pages 253-260.
Crossref
Crossref
Min-ho Kim, D. Neil Granger & Norman R. Harris. (2007) Mediators of CD18/P-selectin-dependent constriction of venule-paired arterioles in hypercholesterolemia. Microvascular Research 73:2, pages 150-155.
Crossref
Crossref
Lihua Yang, Erin Jackson, B. Mark Woerner, Arie Perry, David Piwnica-Worms & Joshua B. Rubin. (2007)
Blocking CXCR4-Mediated Cyclic AMP Suppression Inhibits Brain Tumor Growth
In vivo
. Cancer Research 67:2, pages 651-658.
Crossref
Crossref
Bernd C Kieseier & Heinz Wiendl. (2007) Oral Disease-Modifying Treatments for Multiple Sclerosis. CNS Drugs 21:6, pages 483-502.
Crossref
Crossref
Thomas D. Bethke, Gabriele M. Böhmer, Robert Hermann, Bernhard Hauns, Richard Fux, Klaus Mörike, Michael David, Dietrich Knoerzer, Wilhelm Wurst & Christoph H. Gleiter. (2007) Dose-Proportional Intraindividual Single- and Repeated-Dose Pharmacokinetics of Roflumilast, an Oral, Once-Daily Phosphodiesterase 4 Inhibitor. The Journal of Clinical Pharmacology 47:1, pages 26-36.
Crossref
Crossref
Heinz Wiendl & Reinhard Hohlfeld. 2007. Immune Regulation and Immunotherapy in Autoimmune Disease. Immune Regulation and Immunotherapy in Autoimmune Disease
289
338
.
Mark Giembycz. 2006. Cyclic Nucleotide Phosphodiesterases in Health and Disease. Cyclic Nucleotide Phosphodiesterases in Health and Disease.
Pamela Maher, Tatsuhiro Akaishi & Kazuho Abe. (2006) Flavonoid fisetin promotes ERK-dependent long-term potentiation and enhances memory. Proceedings of the National Academy of Sciences 103:44, pages 16568-16573.
Crossref
Crossref
Brigitte GanterRonald D SnyderDonald N HalbertMay D Lee. (2006)
Toxicogenomics in drug discovery and development: mechanistic analysis of compound/class-dependent effects using the DrugMatrix
®
database
. Pharmacogenomics 7:7, pages 1025-1044.
Crossref
Crossref
Vikrant M. Bhor, Sagarika Dev, Ganga Ramu Vasanthakumar, Parimal Kumar, Sharmistha Sinha & Avadhesha Surolia. (2006) Broad Substrate Stereospecificity of the Mycobacterium tuberculosis 7-Keto-8-aminopelargonic Acid Synthase. Journal of Biological Chemistry 281:35, pages 25076-25088.
Crossref
Crossref
Mark A. Giembycz. (2006) An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease. British Journal of Clinical Pharmacology 62:2, pages 138-152.
Crossref
Crossref
Frank S. Menniti, W. Stephen Faraci & Christopher J. Schmidt. (2006) Phosphodiesterases in the CNS: targets for drug development. Nature Reviews Drug Discovery 5:8, pages 660-670.
Crossref
Crossref
Stefano Pieretti, Luigi Dominici, Amalia Di Giannuario, Nicoletta Cesari & Vittorio Dal Piaz. (2006) Local anti-inflammatory effect and behavioral studies on new PDE4 inhibitors. Life Sciences 79:8, pages 791-800.
Crossref
Crossref
Carlos A. ZarateJrJr, Jaskaran Singh & Husseini K. Manji. (2006) Cellular Plasticity Cascades: Targets for the Development of Novel Therapeutics for Bipolar Disorder. Biological Psychiatry 59:11, pages 1006-1020.
Crossref
Crossref
Lucien C.D. Gibson, Stuart F. Hastings, Ian McPhee, Robert A. Clayton, Claire E. Darroch, Alison Mackenzie, Fiona L. MacKenzie, Michiaki Nagasawa, Patricia A. Stevens & Simon J. MacKenzie. (2006) The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family. European Journal of Pharmacology 538:1-3, pages 39-42.
Crossref
Crossref
Robert J. Chambers, Kristin Abrams, Tessa A. Castleberry, John B. Cheng, Douglas A. Fisher, Ajith V. Kamath, Anthony Marfat, David O. Nettleton, Joann D. Pillar, Eben D. Salter, Alissa L. Sheils, John T. Shirley, Claudia R. Turner, John P. Umland & Kelvin T. Lam. (2006) A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function. Bioorganic & Medicinal Chemistry Letters 16:3, pages 718-721.
Crossref
Crossref
Gregory N. Dietsch, Chris R. Dipalma, Russell J. Eyre, Tuan Q. Pham, Karen M. Poole, Noah B. Pefaur, William D. Welch, Esther Trueblood, William D. Kerns & Suzanne T. Kanaly. (2016) Characterization of the Inflammatory Response to a Highly Selective PDE4 Inhibitor in the Rat and the Identification of Biomarkers that Correlate with Toxicity. Toxicologic Pathology 34:1, pages 39-51.
Crossref
Crossref
Verena von Bülow, Lothar Rink & Hajo Haase. (2005) Zinc-Mediated Inhibition of Cyclic Nucleotide Phosphodiesterase Activity and Expression Suppresses TNF-α and IL-1β Production in Monocytes by Elevation of Guanosine 3′,5′-Cyclic Monophosphate. The Journal of Immunology 175:7, pages 4697-4705.
Crossref
Crossref
Susumu Seino & Tadao Shibasaki. (2005) PKA-Dependent and PKA-Independent Pathways for cAMP-Regulated Exocytosis. Physiological Reviews 85:4, pages 1303-1342.
Crossref
Crossref
Thomas Haack, Raimondo Fattori, Mauro Napoletano, Franco Pellacini, Giovanni Fronza, Giuseppina Raffaini & Fabio Ganazzoli. (2005) Phthalazine PDE IV inhibitors: Conformational study of some 6-methoxy-1,4-disubstituted derivatives. Bioorganic & Medicinal Chemistry 13:14, pages 4425-4433.
Crossref
Crossref
María Jesús Sanz, Julio Cortijo & Esteban J. Morcillo. (2005) PDE4 inhibitors as new anti-inflammatory drugs: Effects on cell trafficking and cell adhesion molecules expression. Pharmacology & Therapeutics 106:3, pages 269-297.
Crossref
Crossref
Songwei WuEugene A. CioffiDiego AlvarezSarah L. SaynerHairu ChenDonna L. CioffiJudy KingJudy R. CreightonMary TownsleySteven R. GoodmanTroy Stevens. (2005)
Essential Role of a Ca
2+
-Selective, Store-Operated Current (
I
SOC
) in Endothelial Cell Permeability
. Circulation Research 96:8, pages 856-863.
Crossref
Crossref
Ana Castro, Maria Jose Jerez, Carmen Gil & Ana Martinez. (2004) Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: Advances in the development of specific phosphodiesterase inhibitors. Medicinal Research Reviews 25:2, pages 229-244.
Crossref
Crossref
Rajiv R. Ratan. (2004) cAMP response element binding protein family transcription factors: The Holy Grail of neurological therapeutics?. Annals of Neurology 56:5, pages 607-608.
Crossref
Crossref
Hiroshi Ochiai, Tazumi Ohtani, Akiharu Ishida, Kensuke Kusumi, Masashi Kato, Hiroshi Kohno, Yoshihiko Odagaki, Katuya Kishikawa, Susumu Yamamoto, Hiroshi Takeda, Takaaki Obata, Hisao Nakai & Masaaki Toda. (2004) Highly potent PDE4 inhibitors with therapeutic potential. Bioorganic & Medicinal Chemistry 12:17, pages 4645-4665.
Crossref
Crossref
Rachael Barber, George S. Baillie, Reinhard Bergmann, Malcolm C. Shepherd, Ruth Sepper, Miles D. Houslay & Gino Van Heeke. (2004) Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. American Journal of Physiology-Lung Cellular and Molecular Physiology 287:2, pages L332-L343.
Crossref
Crossref
J A Quiroz, J Singh, T D Gould, K D Denicoff, C A ZarateJrJr & H K Manji. (2004) Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology. Molecular Psychiatry 9:8, pages 756-776.
Crossref
Crossref
Hiroshi Ochiai, Tazumi Ohtani, Akiharu Ishida, Katuya Kishikawa, Susumu Yamamoto, Hiroshi Takeda, Takaaki Obata, Hisao Nakai & Masaaki Toda. (2004) Orally active PDE4 inhibitor with therapeutic potential. European Journal of Medicinal Chemistry 39:7, pages 555-571.
Crossref
Crossref
H. Wiendl, H. C. Lehmann, R. Hohlfeld, H.-P. Hartung & B. C. Kieseier. (2004) Multiple Sklerose: potenzielle Therapieansätze und Update laufender StudienMultiple sclerosis: potential therapeutic options and update of ongoing clinical trials. Der Nervenarzt 75:6, pages 536-552.
Crossref
Crossref
Dennis S. CharneyHusseini K. Manji. (2004) Life Stress, Genes, and Depression: Multiple Pathways Lead to Increased Risk and New Opportunities for Intervention. Science's STKE 2004:225.
Crossref
Crossref
Hiroshi Ochiai, Tazumi Ohtani, Akiharu Ishida, Katuya Kishikawa, Takaaki Obata, Hisao Nakai & Masaaki Toda. (2004) Orally active PDE4 inhibitors with therapeutic potential. Bioorganic & Medicinal Chemistry Letters 14:5, pages 1323-1327.
Crossref
Crossref
Regina Draheim, Ute Egerland & Chris Rundfeldt. (2004)
Anti-Inflammatory Potential of the Selective Phosphodiesterase 4 Inhibitor
N
-(3,5-Dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic Acid Amide (AWD 12-281), in Human Cell Preparations
. Journal of Pharmacology and Experimental Therapeutics 308:2, pages 555-563.
Crossref
Crossref
Simon J MacKenzie. (2004) Phosphodiesterase 4 cAMP phosphodiesterases as targets for novel anti-inflammatory therapeutics. Allergology International 53:2, pages 101-110.
Crossref
Crossref
Hiroshi Ochiai, Tazumi Ohtani, Akiharu Ishida, Kensuke Kusumi, Masashi Kato, Hiroshi Kohno, Katuya Kishikawa, Takaaki Obata, Hisao Nakai & Masaaki Toda. (2004) Highly potent PDE4 inhibitors with therapeutic potential. Bioorganic & Medicinal Chemistry Letters 14:1, pages 207-210.
Crossref
Crossref
Shashi P. Singh, Edward G. Barrett, Roma Kalra, Seddigheh Razani-Boroujerdi, Raymond J. Langley, Viswanath Kurup, Yohannes Tesfaigzi & Mohan L. Sopori. (2003) Prenatal Cigarette Smoke Decreases Lung cAMP and Increases Airway Hyperresponsiveness. American Journal of Respiratory and Critical Care Medicine 168:3, pages 342-347.
Crossref
Crossref
Yves Ducharme, Richard W Friesen, Marc Blouin, Bernard Côté, Daniel Dubé, Diane Ethier, Richard Frenette, France Laliberté, Joseph A Mancini, Paul Masson, Angela Styhler, Robert N Young & Yves Girard. (2003) Substituted 2-Pyridinemethanol derivatives as potent and selective phosphodiesterase-4 inhibitors. Bioorganic & Medicinal Chemistry Letters 13:11, pages 1923-1926.
Crossref
Crossref
Husseini K Manji, Jorge A Quiroz, Jonathan Sporn, Jennifer L Payne, Kirk Denicoff, Neil A. Gray, Carlos A ZarateJr.Jr. & Dennis S Charney. (2003) Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for Difficult-to-Treat depression. Biological Psychiatry 53:8, pages 707-742.
Crossref
Crossref
Domenico Spina. (2003) Phosphodiesterase-4 Inhibitors in the Treatment of Inflammatory Lung Disease. Drugs 63:23, pages 2575-2594.
Crossref
Crossref
George M. Buckley, Nicola Cooper, Hazel J. Dyke, Fiona P. Galleway, Lewis Gowers, Alan F. Haughan, Hannah J. Kendall, Christopher Lowe, Robert Maxey, John G. Montana, Robert Naylor, Janet Oxford, Joanna C. Peake, C.Louise Picken, Karen A. Runcie, Verity Sabin, Andrew Sharpe & Julie B.H. Warneck. (2002) 8-Methoxyquinoline-5-carboxamides as PDE4 inhibitors: a potential treatment for asthma. Bioorganic & Medicinal Chemistry Letters 12:12, pages 1613-1615.
Crossref
Crossref
Eirini Vagena, Jae Kyu Ryu, Bernat Baeza-Raja, Nicola M. Walsh, Catriona Syme, Jonathan P. Day, Miles D. Houslay & George S. Baillie. (2018) A High-fat Diet Promotes Depression-like Behavior in Mice by Suppressing Hypothalamic PKA Signaling. SSRN Electronic Journal.
Crossref
Crossref